QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma, modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
Did you know Quantify is an ENCePP partner conducting PASS studies
Since 2020, Quantify Research has been a proud partner to the European Medicines Agency-coordinated ENCePP (European Network for Centres of Pharmacoepidemiology and Pharmacovigilance) initiative.
This network brings together expertise and resources in pharmacoepidemiology and pharmacovigilance across Europe with the aim of conducting high quality, multi-center, independent Post Authorization Safety Studies (PASS) with a focus on observational research.
Quantify has executed a variety of imposed- and non-imposed PASS studies […]
SHEA Conference!
The Quantify team had a great first day at SHEA!
The team contributed to a theme session, an oral presentation and a poster presentation, and had the opportunity to reconnect with many familiar faces.
We are looking forward to meeting many more tomorrow!
❗ Don´t miss Quantify at SHEA Conference ❗
Quantify’s Emilie Toresson Grip, Olivia Ernstsson, Johan Liseth Hansen, Konstantin Macheridis and Linnea Oldsberg are looking forward to (re)connecting with our fellow Swedish health economists at SHEA in Uppsala early next week!
Make sure to catch the team’s exciting presentations on Monday 15th:
💡 Emilie Toresson Grip will lead a theme session on how regional data […]
How will the EH HTA regulation and JCA affect Nordic pharma affiliates?
▪ 𝐋𝐨𝐜𝐚𝐥 𝐚𝐟𝐟𝐢𝐥𝐢𝐚𝐭𝐞𝐬 𝐦𝐚𝐲 𝐩𝐥𝐚𝐲 𝐚𝐧 𝐢𝐦𝐩𝐨𝐫𝐭𝐚𝐧𝐭 𝐫𝐨𝐥𝐞 𝐢𝐧 𝐭𝐡𝐞 𝐏𝐈𝐂𝐎 𝐬𝐢𝐦𝐮𝐥𝐚𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐬𝐜𝐨𝐩𝐢𝐧𝐠 𝐩𝐫𝐨𝐜𝐞𝐬𝐬: EU teams will rely on Nordic affiliates to provide local market information for PICO simulation and preparation.
Moreover, local affiliates may become an important point of influence for ‘health technology developers’ (HTDs) in the PICO process.
Involvement of the HTD in the scoping and PICO creation process, as currently drafted, is very limited.
If this set-up prevails local impact […]